HOME >> BIOLOGY >> NEWS
Phase 3 psoriatic arthritis data for ENBREL (etanercept) announced at a national scientific meeting

n ACR20 response compared to 15 percent of 104 patients receiving placebo, after 12 weeks of treatment.
  • 72 percent of patients receiving ENBREL achieved a treatment response compared to 31 percent of patients receiving placebo after 12 weeks of treatment, using the PsARC measurement.
  • 54 percent of patients receiving ENBREL for 24 weeks were assessed as having clear or almost clear skin manifestations, as measured by the dermatologists global assessment, compared to 23 percent of patients receiving placebo. At baseline, 20 percent of patients in each group were clear or almost clear of skin disease.
    Also in this study, a subset (62 patients receiving ENBREL and 66 patients receiving placebo who had greater than 3 percent of their body covered by psoriatic plaque) were evaluated for psoriasis activity. Results showed that:
  • 23 percent of patients receiving ENBREL improved by 75 percent or better compared to 3 percent of patients receiving placebo, as measured by the psoriasis area and severity index (PASI) score.

    Adverse events were similar to those reported in previous trials of ENBREL in patients with rheumatoid arthritis. There was no increase in the number of serious adverse events occurring in patients receiving ENBREL as compared with those receiving placebo. Only the rate of injection site reactions (ISRs) in patients receiving ENBREL was statistically different compared to placebo (36 percent vs. 9 percent).

    These data are currently being reviewed by the U.S. Food & Drug Administration (FDA) for potential approval of ENBREL for the treatment of psoriatic arthritis. In September, the FDA granted priority review status requiring that the FDA act on the supplemental Biologics License Application (sBLA) within six months of submission date. Immunex submitted its sBLA for ENBREL on July 16, 2001. ENBREL is the first product to be reviewed by the FDA for the treatment of psoriatic arthritis.

    We are worki
    '"/>




    • 12-Nov-2001


    Page: 1 2 3 4 5

    Related biology news :

    1. Phase II trials of second-generation antisense cancer drug planned following successful early study
    2. OneWorld Health completes enrollment, treatment in Phase III India trial
    3. Landmark, pivotal Phase IIb/III trial of biotoxin for cancer pain begins
    4. VaxGen reports Phase I clinical trial results of anthrax vaccine candidate
    5. Critical Therapeutics launches Phase I clinical trial of anti-inflammatory compound
    6. KEPPRA international Phase IV SKATE study results show favourable efficacy
    7. Phase III study results with Raptiva in the treatment of psoriasis presented at Annual AAD meeting
    8. Phase III, 48-Wk NEAT study results comparing GW433908 to Nelfinavir presented today
    9. OXiGENE announces commencement of Phase I/II clinical trial of Combretastatin A4 Prodrug
    10. Acorda therapeutics receives NIH Phase 2 grant for central nervous system repair
    11. Phase transition in bilayers could affect their performance

    Post Your Comments:
    (Date:5/16/2013)... Philadelphia, PA, May 16, 2013 The relationship ... intelligence (IQ) has not been clear. Schizophrenia is ... functional disability. There are clues that reduced IQ ... schizophrenia. For example, reduced cognitive ability may precede ... may be present in healthy relatives of people ...
    (Date:5/16/2013)... May 16, 2013 Integrated Biometrics patented ... a custom thin film transistor camera introduces Sherlock, ... roll image in the smallest and lightest form ... Appendix F Mobile ID FAP 45, Certified scanner ... in size and weight when compared to optical ...
    (Date:5/16/2013)... about 23 million years old give unprecedented insight ... one of the most species-rich groups among the ... Professor Bettina Reichenbacher from the Division of Paleontology ... Environmental Sciences at Ludwig-Maximilians-Universitaet (LMU) in Munich / ... fossils which they assign to the group of ...
    Breaking Biology News(10 mins):Genetic risk for schizophrenia is connected to reduced IQ 2Paleontology: The eloquence of the otoliths 2Paleontology: The eloquence of the otoliths 3
    (Date:5/17/2013)... USA (PRWEB) May 17, 2013 •    First ... Globes Certified for sustainability ,     New facility will ... , Syngenta unveiled its new ... at the company’s RTP Innovation Center. The first of ... researchers to simulate any agricultural climate and precisely measure ...
    (Date:5/17/2013)... 2013 /PRNewswire-iReach/ -- Aridis is pleased to announce ... Switzerland -based Kenta Biotech to acquire ... (mAb) products, and technologies. This asset portfolio purchase ... of infections by common pathogens including drug resistant ... Pseudomonas aeruginosa , Acinetobacter baumannii and ...
    (Date:5/17/2013)... May 17, 2013 RURO Inc. ... version 4.1, a versatile refinement to the smart ... solution, improves its advanced methodical management for transgenic ... ezColony 4.1. The network-based platform provides user access ... research. While continuing to emphasize streamlined tasks, such ...
    (Date:5/16/2013)... (PRWEB) May 16, 2013 The ... by Global Cooling, Inc., Athens, OH, USA, won the ... by the International Society for Biological and Environmental Repositories ... award, given to one product annually, recognizes the company’s ... ultra-low temperature freezer. The award was presented to ...
    Breaking Biology Technology:Syngenta Opens Unique $72 Million Advanced Crop Lab 2Syngenta Opens Unique $72 Million Advanced Crop Lab 3Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2Stirling Ultracold Ultra-Low Freezer Wins 2013 Outstanding New Product Award at International Biorepository Conference, Sydney, Australia 2
    Cached News: